维普期刊资源整合服务平台（V6.5）

151篇 您的检索式：作者名="Strumberg"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors显示文摘	STRUMBERG D RICHLY H HILGER RA	2005	J Clin Oncol2005，23，5：	1
2	Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors显示文摘	Strumberg D Richly H Hilger RA	2005	J Clin Oncol2005，23，：	1
3	Phase I dose escalation study of telatinib (BAY 5729352) in patients with advanced solid tumours显示文摘	Strumberg D Schultheis B Adamietz I A	2008	Br J Cancer2008，99，10：	1
4	Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43-9006 in patients with advanced refractory solid tumors显示文摘	Strumberg D Richly H Hilger RA	2005	J Clin Oncol2005，23，5：	1
5	Pooled analysis of BAY 43-92006 (sorafenib) monotherapy in patients with advanced solid turnouts: is rash associated with treat- ment outcome? 显示文摘	Strumberg D Awada A Hirte H	2006	Eur J Cancer2006，42，4：	1
6	Importance of the fourth alpha-helix within the CAP homology domain of type Ⅱ topoisomerase for DNA cleavage site recognition and quinolone action显示文摘	STRUMBERG D NITISS JL DONG JW	2002	Antimicrob Agents Chemother2002，46，9：	1
7	Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment显示文摘	Strumberg D	2005	Drugs Today(Barc)2005，41，12：	1
8	The Ras-RafMEK-ERK pathway in the treatment of cancer显示文摘	Hilger RA Scheulen ME Strumberg D	2002	Onkologie2002，25，6：	1
9	Microfluidic device for combinatorial fusion of liposomes and ceils 显示文摘	Strumberg A Karlsson A Rytt sen F	2001	Anual Chem2001，15，：	1
10	Pooled safety analysis of BAY 43 - 9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? 显示文摘	Strumberg D Awada A Hirte H	2006	Eur J Cancer2006，42，：	1
11	Phase Ⅱ study of nimotuzumab,a humanized monoclonal anti-epi- dermal growth factor receptor (EGFR) antibody in patients with locally advanced or metastatic pancreatic cancer显示文摘	Strumberg D Schuhheis B Scheulen ME	2012	Invest New Drugs2012，30，3：	1
12	Regorafenib for cancer显示文摘	Dirk Strumberg Beate Schultheis	2012	Expert Opinion on Investigational Drugs2012，，6：	1
13	Results of a Phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors显示文摘	Richly H Henning B F Strumberg D	2006	Ann Oncol2006，17，5：	1
14	Pooled safety analy- sis of BAY 43-9006 (sorafenib)monotherapy in patients with advanced solid tumours:Is rash associat-ed with treatment out- come显示文摘	Strumberg D Awada A Hirte H	2006	Eur J Cancer2006，42，4：	1
15	Phase Ⅰ dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours显示文摘	Strumberg D Schultheis B Adamietz IA	2008	Br J Cancer2008，99，10：	1
16	Phase II, randomized, double-blind placebo-controlled trial of ni- motuzumab plus gemcitabine compared with gemcitabi- ne alone in patients (pts) with advanced pancreatic can- cer (PC) 显示文摘	Strumberg D Schultheis B Ebert MP	2013	J Clin Oncol2013，，31：	1
17	Safety,pharmacokinetics,and preliminary antitumor activity of sorafenib:a review of four phase Ⅰ trials in patientswith advanced refractory solid tumors显示文摘	Strumberg D Clark JW Awada A	2007	Oncologist2007，12，4：	1
18	Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study 显示文摘	Strumberg D Scheulen M E Schultheis B	2012	Br J Cancer2012，106，11：	1
19	Safety, pharmacokinetics, and pre- liminary antitumor activity of sorafenib: a review of four phage 1 trial in patients with advanced refractory solid tumors显示文摘	Strumberg D Clark JW Schwartz B	2007	Oncologist2007，12，4：	1
20	Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma显示文摘	Strumberg D Erhard J Harstrick A		0，，08：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示